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Abstract
Peptide ligands of G protein-coupled receptors constitute valuable natural lead structures for the development of highly
selective drugs and high-affinity tools to probe ligand-receptor interaction. Currently, pharmacological and metabolic
modification of natural peptides involves either an iterative trial-and-error process based on structure-activity relationships
or screening of peptide libraries that contain many structural variants of the native molecule. Here, we present a novel
neural network architecture for the improvement of metabolic stability without loss of bioactivity. In this approach the
peptide sequence determines the topology of the neural network and each cell corresponds one-to-one to a single amino
acid of the peptide chain. Using a training set, the learning algorithm calculated weights for each cell. The resulting network
calculated the fitness function in a genetic algorithm to explore the virtual space of all possible peptides. The network
training was based on gradient descent techniques which rely on the efficient calculation of the gradient by back-
propagation. After three consecutive cycles of sequence design by the neural network, peptide synthesis and bioassay this
new approach yielded a ligand with 70fold higher metabolic stability compared to the wild type peptide without loss of the
subnanomolar activity in the biological assay. Combining specialized neural networks with an exploration of the
combinatorial amino acid sequence space by genetic algorithms represents a novel rational strategy for peptide design and
optimization.
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Introduction
G protein-coupled receptors (GPCRs) regulate vital cellular
functions such as energy and ion homeostasis, cellular adhesion,
motility and also proliferation [1,2]. For their involvement in
many physiological processes relevant in diseases ranging from
diabetes to cancer, GPCRs are considered one of the most
valuable classes of protein targets on the cell membrane [2,3]. At
least one third of all currently marketed drugs are directed against
GPCRs, while due to the lack of highly potent and stable ligands
many other receptors of this protein superfamily still await their
pharmaceutical use [4]. In this target class, structure-based drug
discovery using rational design is still hampered by the small
number of available 3D data for GPCRs. When this study was
initiated only five x-ray structures of GPCRS were known: those of
of two rhodopsins (PDB 1F88, 2Z73) [5,6], of the b2- and b1-
adrenergic receptors (PDB 2RH1, 2VT4) [7,8] and the structure
of the A2A adenosine receptor (PDB 2RH1) [9]. Within the last
two years the structures of the CXC chemokine receptor type 4
(PDB 3OE0, 3ODU) [10], dopamine D3 receptor (PBD 3PBL)
[11] and the histamine H1 receptor (PDB 3RZE) [12] were
determined. Thus, CXCR4 is the only peptide/protein ligand
GPCR with a known three-dimensional structure so far. Conse-
quently, alternative approaches for molecular design of potential
drugs are being explored. Evolutionary strategies allow the
optimization of a molecule’s properties by a cyclic process
consisting of consecutive variation and selection steps [13]. For
this stepwise improvement of molecular parameters, no a priori
knowledge of quantitative structure-activity relationships (QSAR)
is required and the whole process may take place in vitro, in vivo or
even in silico by computer-based algorithms.
The common QSAR approach consists of two main elements
that could be considered as coding and learning [14]. The learning
part can be solved with standard machine learning tools. Artificial
neural networks are commonly used in this context as nonlinear
regression models that correlate biological activities with physio-
chemical or structural properties. The coding part is based on
identification of molecular descriptors that encode essential
properties of the compounds under investigation [14]. Alternative
approaches of classical machine-learning-based QSAR described
above circumvent the problem of computing and selecting
a representative set of molecular descriptors. Therefore molecules
are considered as structured data – represented as graphs –
wherein each atom is a node and each bond is an edge. These
graphs define the topology of a learning machine. This is the main
concept of the molecular graph network [15], the graph machines
[16] and the graph neural network model [17] in chemistry which
translate a chemical structure into a graph that works as a topology
template for the connections of a neural network.
Artificial neural networks are computer programs inspired by
nature that were intended to process complex information in
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e36948a manner similar to the human brain [18,19]. Although they did
not fulfill the high expectations of the early days, they evolved into
useful non-linear statistical modeling tools. In this role they have
been successfully used in the QSAR field, generating hypotheses in
the drug design cycle for GPCRs and other target classes and in
automated feature extraction, yielding convincing results in
numerous projects for small molecule drug development [19–
25,25]. Artificial neural networks have also generated very
substantial progress in the optimization of peptides for various
purposes in molecular biology and pharmaceutical design, for
instance in MHC I binding and stabilizing peptides [26–28], for
the identification and biological activity of signal peptidase and
viral proteinase cleavage sites [29–31], with cell-interacting
peptides [32], and in modifying peptide transport across the
blood-brain barrier [33]. Schneider et al. [34] have used artificial
neural networks and a computer-based evolutionary search to
design autoantibody-binding peptides by a cyclic variation-
selection process. Using multiple iterations of synthesis, assay
and computer-based molecular design, Riester et al. [35] were
able to identify enhanced peptidic thrombin inhibitors. Their
approach was based on an efficient type of genetic algorithm [36].
Currently, the optimization process for GPCR peptide ligands
involves traditional and modern approaches in medicinal chem-
istry, as reviewed in [37]. So far, the optimization of GPCR
peptide ligands by artificial neural networks has not been
described.
In this work, we follow the idea of translating chemical structure
directly into the topology of a learning machine. Our strategy is
focused on peptides, wherein the sequence of amino acids
determines the topology of the neural network. Each cell in the
network corresponds one-to-one to an amino acid in the peptide.
Learning the QSAR means adopting the weights of the cells in the
network with respect to the quantity of interest (in general the
activity or the metabolic stability). The architecture of this neural
network fits into the concept of the Graph Neural Network [17].
In contrast to the Self Organizing Maps (also known as Kohonen
maps [38]) they are trained using supervised learning and the
topology is defined by the peptide sequence. The adapted cells are
used to build models for the QSAR of new virtual peptides in
order to optimize the desired property in silico. We explore the
multidimensional space of all possible peptides with a genetic
algorithm (GA) wherein the output of the GNN model defines the
fitness function of the GA. Only the top ranking virtual peptides
are selected for synthesis and in vitro testing in order to produce
new measurements for the next optimization cycle.
Chemerin is a 163 amino acid polypeptide identified as a natural
ligand for the heptahelical transmembrane receptor CMKLR1
[39]. Initially, the chemerin gene (also known as retinoic acid
receptor responder 2 [RARRES2] or tazarotene-induced gene
[TIG2]) had been identified as a novel retinoid-activated gene in
skin [40]. It has been reported to be involved in the regulation of
immune responses and adipogenesis, being engaged in a variety of
physiological functions [41–47]. Its precursor molecule prochem-
erin is proteolytically activated and finally inactivated in sequential
steps, modulating its physiological role in tissues [48–50].
Chemerin-9 (chemerin 148–156) was previously identified as
a peptide mimic of full-length chemerin showing low nanomolar
potency [51,52]. Chemerin is also measurable in a number of
human inflammatory exudates, including ascitic fluids from
human ovarian cancer and liver cancer, as well as synovial fluids
from arthritic patients. In the wake of chemerin’s role as an
adipokine and inflammatory modulator, a stabilized CMKLR1
ligand of high affinity may be beneficial in the treatment of
metabolic syndrome and chronic inflammatory diseases.
By applying several cycles of peptide synthesis, testing in
bioassays and GNN-based sequence optimization we have
gradually improved the metabolic stability of a CMKLR1
nonamer peptide ligand with agonistic properties. For the first
time, we describe the application of a novel GNN technology for
the optimization of a small peptide for potential pharmaceutical
application. By using this approach, we were able to achieve
a 70fold improvement of the metabolic half life (tK =1693 min) in
a ligand with subnanomolar activity in the biological assay (EC50
=0.49 nM).
Results
Graph Neural Networks and Genetic Algorithms
The GNN was designed to reflect the topology of a peptide by
mimicking the sequence and the type of the constituting amino
acids. Each amino acid had a representation as a particular
elementary cell in the network with individual weights that were
adjusted during the network training. Figure 1 shows a schematic
plot of an elementary cell together with the weight vector that
defines the connections to the neighboring cells of the network.
GNN training was initiated by feeding in the peptides’ current
sequences and biochemical properties such as agonistic activity
and metabolic stability (Fig. 2). The training procedure was based
on stochastic gradient descent with several improvements that
make the training of the shared weights feasible [53]. The
application of GNN-based molecular optimization was organized
in a circular fashion (Fig. 2). From a start population of molecule
sequences derived from established knowledge, peptides were
synthesized and their properties were determined using the
appropriate biochemical or cellular assay.
A GNN was then trained as described above and the adapted
cells worked as building blocks of new virtual peptides that were
generated by rearranging the order of the cells. The resulting
GNN-model defined the fitness function in a GA that was
generating an ensemble of improved peptide sequences entering
the next cycle of development.
Generation of an initial set of peptide variants (cycle 0)
In order to generate a diversity of structural variants in round
0 of the optimization process, 30 different sequences were derived
from modifications of the native nonamer of chemerin-9. These
variants were synthesized as peptide amides and subjected to EC50
determination for agonistic activity on HEK293 cells transfected
with CMKLR1, the receptor for chemerin (start population or
input, data not shown). In this initial round of screening, we
explored the capacity for the exchange against other (natural) L-
amino acids and stabilizing D-amino acids in the activation assay –
no stability data were obtained at that stage. To allow better
comparison with data from later cycles, the five peptides with the
best EC50 values were resynthesized with a free acid function at
the C terminus and were analyzed for their EC50 and metabolic
stability (Table 1, cycle 0). As can be seen from the comparison
with data from the native nonamer chemerin-9 (Table 1, bottom
line), this initial round did not improve the mean stability of the
peptide variants. Instead, half life of all these peptides in human
serum was similar to the wild-type molecule (24 mins).
GNN improvement (cycle 1–3)
Round 1 to 3 of the optimization process included at least 34
different sequences each from a GNN model as described above
(Table S1). These variants were synthesized as peptides with a free
acid function at their carboxy terminus and were subjected to
EC50 determination for agonistic activity on HEK293 cells
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PLoS ONE | www.plosone.org 2 May 2012 | Volume 7 | Issue 5 | e36948Figure 1. (A) Graph Neural Networks consist of interconnected elementary cells. The internal weight of the cell is given by winternal and the feedback
during the iteration of the GNN is controlled by v0. The inputs from the neighboring cells are connected with the weights v-N,…,N preserving the
order of the peptide sequence as shown in (B). The sum of the weighted inputs passes the activation function and forms the output of the cell for the
next iteration step of the network. (B) The translation process of a peptide into a fully connected GNN. Note the one-to-one correspondence between
the amino acids of the peptide and the elementary cells of the GNN. The network is iterated through time and the output of the network is the sum
over all internal states after the final iteration.
doi:10.1371/journal.pone.0036948.g001
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explored the capacity for the exchange against other (natural) L-
amino acids and also stabilizing D-amino acids in the activation
assay, as well as the metabolic stability of the various compounds.
As can be seen from the comparison with data from the native
nonamer chemerin-9 (Table 1, bottom line), and with results from
round 0, the following rounds of optimization yielded a marked
improvement in metabolic stability while retaining high agonistic
activity. Quite obvious is the gradual enhancement over the three
rounds: both bioactivity (EC50) and half-life of the peptides
improve from first to third cycle (Fig. 3 A and B).
Analysis of the five best peptides from each cycle
To analyze the structure-activity relationships in the process of
GNN optimization, multiple sequence alignments of the five best
peptides from each cycle were compared (Fig. 3C). The sequences
from cycle 0 (input or start population) showed moderate
conservation across the peptide, with higher variability towards
the carboxyterminal portion. Here, at the beginning of the
evolutionary process, the consensus sequence of these five peptides
still corresponded to the chemerin-9 wild type sequence (Fig. 3C,
upper left graph). The aromatic amino acids at positions 1, 2 and 8
as well as the sterically peculiar Pro
3 and Gly
4 were well
conserved. The only exception was found in a single exchange
of Phe
2 by Leucin. The same peptide also showed the only
inclusion of a D amino acid (D-Phe
7) which, however, did not lead
to any improvement in stability over the wild type (Table 1, 2
nd
and last line). Position 9 is Serin in the wild type, but it obviously
easily accommodates exchanges with either aromatic or small
hydrophobic amino acids (Phe or Gly).
Within the five best sequences of cycle 1 (Fig. 3A, upper right
graph), the Leu
2 introduction from cycle 1 was further inherited,
dominating this position with only one exception (Val
2). Again,
Pro
3 and Gly
4 were unchanged in addition to the aromatic
position 1, Glu
5 and Phe
8. Both these trends lead to a consensus
sequence close to wild type, with only position 2 substituted by
Leu, while position 9 was variable. In this set of peptides, the first
significant improvement in stability is associated with the de novo
Figure 2. GNNs are trained and then optimized. This example illustrates the GNN’s mode of action in computer-assisted peptide design: In the
training set, the model is taught the properties of the current peptides (biological activity, stability) and the adopted cells build virtual peptides that
are evaluated in the genetic algorithm-based optimization. The peptide optimization process is organized in multiple consecutive cycles. The start
population of peptides is based on experts’ knowledge concerning the target, e.g. natural ligands, known analogs or compounds that bind to similar
targets. The trained GNN is used as a fitness function in a genetic algorithm. Newly generated sequences then have to be synthesized and analyzed in
biological assays, before the next GNN training is initiated.
doi:10.1371/journal.pone.0036948.g002
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(Table 1, 10
th and last line), increasing the half life by a factor of 5.
Two peptides with a D amino acid at the carboxy terminus did not
show prolonged stability.
In cycle 2 of the GNN optimization, however, the algorithm
continued to introduce carboxyterminal D amino acids and to
a lesser extend also at the amino terminus, while no internal
positions of the five best peptides in this round contain the D
isoform. Here, the combination of D amino acids at both termini
yields the first peptide with considerably higher stability, increasing
the half life by a factor of 48 to 1157 minutes (Table 1). Positions 3
to 8 were completely conserved in this set of peptides, including
Tyr
6, first introduced in cycle 1. The consensus sequence
consequently differs in positions 2 and 6 from the wild type
(Fig. 3A, lower left graph).
Cycle 3, as the previous cycle, yielded a novel exchange at
a previously conserved position, leading to two peptides with
additional improvement of stability as well as enhanced activity:
Gly
4 is substituted by D amino acids. Of these substitutions, D-Ser
proved to be most effective, leading to stabilities of 1408 and
1693 minutes (59fold and 70fold improvement, respectively). At
the same time, D-Ser lead to a peptide with subnanomolar activity
at the chemerin receptor (0.49 nM, data highlighted in bold in
Table 1). In this cycle, the five best peptides showed high
conservation at all other positions, with some variability towards
the carboxy terminus. The consensus sequence in this last round
differed in four positions (2, 4, 6, 9) from the original chemerin-9,
the exchange of Gly by D-Ser at position 4 being the most
prominent one (Table 1 and Figure 3A, lower right graph).
The effectiveness of the GNN-based modulation of the peptide
composition are visualized in plots for both parameters analyzed
within this process (Fig. 4). While in the first round, the majority of
data points were found in the lower right quadrant with poor
stability and activity, in cycles 2 and 3 the data cloud was shifted
towards the upper left, representing improved activity and
stability.
Discussion
We presented a Graph Neural Network (GNN) that utilizes
individual processing elements as building blocks with a one-to-
one correspondence to the amino acids of the peptide. The GNN
mimics the linear design of a peptide molecule and converts this
chemical architecture directly into the topology of a learning
machine. This strategy eliminates the obstacle of designing and
computing molecular descriptors for QSAR. In addition, the
GNN requires no preexisting structural knowledge about the drug
target. The scarcity of available 3D structural information on
GPCRs and other membrane-bound proteins thus does not limit
the GNN concept. The novelty of our approach lies in the
topology preserving network structure that mimics the peptide
chain and in that the learning takes place in the weights of the cells
Table 1. Sequences and bioassay data of the five best peptides from each cycle.
optimization cycle peptide sequence activity: EC50 6SD [nM] stability: t1/2 6SD [min]
0 YFPGNFAFS 9.9664.42 1662
0 YLPGQFfFS 0.7760.37 2463
0 YFPGQYAFF 1.8960.90 2668
0 YFPGQFAFG 0.7960.54 1361
0 YFPGHFAFS 6.6362.91 1764
1 FLPGQYAFS 2.7560.14 2861
1 YLPGQYAFL 5.7562.56 2764
1 YLPGQFAFs 1.7260.32 3160
1 YVPGQFAFf 4.1762.31 42619
1 yLPGQYAFF 9.2363.68 135639
2 fLPGQYAFf 8.2063.96 1157641
2 YLPGQYAFf 0.2160.22 3664
2 YLPGQYAFs 0.4060.23 2262
2 yLPGQYAFS 3.6262.91 7765
2 YRPGQYAFs 8.6265.01 2164
3 YLPaQYAFs 4.4263.41 110626
3 YLPGQYwFf 3.2461.02 159656
3 YLPqQYAFf 4.2461.87 87619
3 yLPsQYAFf 0.4960.13 16936291
3 yLPsQYAFs 2.9061.34 1408685
chemerin-9 YFPGQFAFS 1.2961.54 2466
Peptides from the initial population are designated as from cycle 0. In the peptide sequences, wild type amino acids are given in standard font. Exchange by a different
L amino acid is represented by a character in bold, D isomers are in addition indicated by lower-case letters. Activities are intracellular calcium mobilization data given as
mean of three independent experiments 6 standard deviation. Stabilities are peptide half life data from an HPLC assay, given as mean of three independent
experiments 6 standard deviation. Data in bold indicate the best peptide in this study, showing approximately 70fold higher stability and 2.5fold higher potency than
the wild-type peptide chemerin-9.
doi:10.1371/journal.pone.0036948.t001
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adapted cells, we are able to assemble new virtual peptides and the
resulting GNNs define the fitness function in a genetic algorithm
that is used to search for new peptides.
The feasibility of this approach was demonstrated in the
construction and optimization of CMKLR1 ligands in an iterative
process of three design cycles of computer-assisted optimization
with respect to the biological activity and metabolic stability of the
peptides. Every round of optimization included synthesis of
candidate molecules, characterization of these peptides in bio-
activity and stability assay, and algorithmic processing of the data
to generate or improve the GNN that links compound structure
and molecular properties. This in turn generates a new set of
peptide sequences. Starting from an initial set of randomly chosen
chemerin-9 variants, a multiparameter optimization was carried
out in three molecular design cycles. We investigated 9-mer
peptides from an alphabet consisting of the 20 natural proteino-
genic amino acids and 15 D-amino acids. Synthesis and
experimental fitness determination of less than 160 different
compounds from the resulting virtual combinatorial library of
more than 7.8610
13 peptide nonamers were necessary to achieve
this goal. Our GNN strategy together with the GA-based
exploration of the combinatorial peptide space is the core concept
of a novel peptide optimization process in drug discovery. It allows
one to efficiently screen the huge chemical space generated by the
combinatorial explosion of possible virtual peptide sequences. For
the first time, artificial neural networks were used to substantially
improve the properties of a peptide receptor ligand.
Various types of artificial neural networks have been utilized to
enhance structure-function optimization with many different
Figure 3. As peptide sequences evolve, metabolic stability of the peptides improves while their biological activity is retained.
Upper panel (A+B): depiction of EC50 values of the receptor activating potency (A) and of the metabolic stability (B, =t1/2) for the three GNN-based
optimization rounds. Both graphs show all the peptides from a given round, sorted according to their activity in the parameter on the y axis. With
receptor activity, low EC50 values are favorable, while in the stability parameter t1/2, high values are to be achieved. Lower panel (C): Peptide sequence
comparisons by multiple alignments illustrate the evolution over the different steps of the process. Four sets of alignments represent the start
population (=input) and three optimization rounds.
doi:10.1371/journal.pone.0036948.g003
Figure 4. Stability and activity of chemerin peptides improve over three cycles. Upper panel: The complete data set from three
optimization rounds is shown, each dot representing one peptide and its properties. The trend points to the upper left part of the diagram, i.e.
peptides that combine high receptor activity (=low EC50) with high metabolic stability. Lower panel: separate representations of the data from all
three rounds. While in the first round, the majority of data points is found in the lower right quadrant with poor stability and activity, in cycles 2 and 3
the data cloud is shifted towards the upper left, representing improved activity and stability. Quality is a measure of the likelihood of observing the
substitutions in a particular column of the alignment [62].
doi:10.1371/journal.pone.0036948.g004
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the artificial neural network design of peptides, identifying novel
sequences that block anti-b1-adrenoreceptor autoantibodies.
Starting from a single seed peptide, these authors trained their
neural networks on sequence-activity relationships to generate de
novo peptide sequences with considerable biological activity. In
contrast, the peptides with the most favorable properties from our
study still retain a common sequence pattern with wild-type
chemerin-9; P
3,Q
5,A
7,F
8 are present in the two best peptides. In
addition, Y
1 is changed to a D-amino acid and F
2 and F
6 are
conservatively exchanged for L or Y. Even among peptides with
lower stability but retained high activity, few variations from the
native YFPGQFAFS sequence of chemerin-9 occur.
Riester et al. (21) organize their optimization process in design
cycles starting with a randomly chosen set of molecules. They run
a GA on the sequence level that has been tailored to meet the
demands of de novo drug design (small training sets, fast
convergence, and few design cycles). In contrast to this approach,
we run a GA on the building blocks of a GNN model that was
designed to cover possible interactions between distant amino
acids. In this way, the GNN approach is much more adaptive than
a static sequence based GA because it translates chemical structure
directly into the topology of a learning machine. The past years
have seen a steady increase of reports on the role of chemerin in
a variety of physiological processes as well as in disease conditions,
ranging from inflammation to diabetes, obesity and hypertension
(for a review, see [55]). Still, the exact role of chemerin in these
disorders remains to be elucidated and further research is required
to determine the significance of high serum levels in corresponding
patients. However, new data on disease pathology will potentially
unravel novel therapeutic approaches that may involve stable
analogs derived from the short active peptide chemerin-9.
Shimamura et al. [56] have recently reported a different
approach to generate stabilized chemerin-9 variants. They
substituted amino acid positions at predicted protease cleavage
sites and analyzed the effect of these modifications by HPLC and
mass spectrometry. Using the same readouts as in this study (Ca
2+
mobilization and serum stability assay), the authors were able to
create a chemerin-9 variant with a reported half-life of .240 min.
The peptide contains one non-natural building block and three
more D-amino acids and has an EC50 in the Ca
2+ mobilization
assay of 22 nM. While the peptide from our own study showed
a half-life of nearly 1700 minutes, the utility of this molecule for in
vivo use still needs to be demonstrated by an in vivo pharmaco-
kinetic study. However, the prolongation of the peptides’
metabolic stability in serum by a factor of 70 appears to be a very
promising starting point for the translation of this molecule into
a therapeutic entity.
Materials and Methods
Neural Network Designs
The building blocks of a GNN are the elementary cells that are
in silico representations of the amino acids in the peptide. An
elementary cell has a weight vector containing an internal weight
and weights that control the interactions with neighboring cells.
The elementary cells are connected to form a chain with one-to-
one correspondence between the amino acids that build the
peptide and the cells in the network. The internal weight of the cell
is w, the inputs from the neighboring cells are connected with the
weights v{N,:::,N and the feedback is controlled by v0. The
weights are combined in the weight vector ~ v v. The translation of
a peptide sequence into a GNN is based on the one-to-one
correspondence between the amino acids of the peptide and the
elementary cells of the GNN. The GNN is iterated several times
which governs the system dynamics. The number of iterations T is
set to be the average length of the sequences under investigation.
The state of the i-th GNN cell yt
i evolves for iterations t=0,…,T-1
according to:
xtz1
i ~winternalz~ y yt~ v v
ytz1
i ~tanh xtz1
i
  
The output of the GNN is the average of the internal states after T
iterations.
Training GNN Models
Training a GNN is put to effect by minimizing the training
error with respect to the network weights based on stochastic
gradient descent. The true gradient is approximated by the
gradient of the loss function which is evaluated on single training
samples. The network weights are adjusted by an amount
proportional to this approximate gradient. A training sample
consists of two parts: The first part is the peptide sequence~ S Si that is
a composition of the M possible amino acids taken from the
alphabet. The second part is the measured activity ai that could be
a continuous value or a class label. We assume to have a collection
of K training samples (~ S Si,ai)i~1,...,K and the weight vectors ~ v vj of
the individual cells in the network that correspond to the M
different amino acids in the alphabet are organized in the weight
vector V~ ~ v v1,...,~ v vM ðÞ : Let f ~ S S1,V
  
denote the output of the
GNN for a given sequence ~ S Si with respect to the network weights
V This output value has to be compared to the training label ai by
means of a loss function l : ðÞ :The loss function measures the
deviation of the network output from the desired value ai. The
training error E V ðÞ is simply the loss averaged over the entire
training set
E V ðÞ ~
PK
i~1 l f ~ S S1,V
  
{a1
  
:
Training the network means minimizing the training error with
respect to the network weights Vbased on stochastic gradient
descend. The stochastic gradient descent performs a series of very
small consecutive steps, determining the direction of each step
from the gradient of an individual error term of the form
d
dV
l f ~ S S1,V
  
{a1
   hi
:
After each step, the new weights V are re–inserted into the loss
function before the next gradient is computed. This defines an
update rule for the weights of the form:
Vi~Vi{1{DVi
with i=1,…,K wherein K is the number of training samples. The
update DVi depends on the i-th training sample only and is given
by
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d
dV
l f ~ S S1,V
  
{a1
   hi
We calculate the update DVi with the standard error back-
propagation technique as it is used for the common feed-forward
multilayer neural network. Details of the training procedure are
described in Wichard et al. [39]. The parameter m controls the
step size of the gradient descend. The initial step size is already
small (around m=0.01) and it is decreased after each training
epoch with a constant factor. This is necessary to achieve a slow
convergence of the weights. Note that in each training step only
a few selected values of the entire weight vector V are adjusted,
namely the ones that correspond to amino acids that appear in the
sequence of the training sample.
In order to build models with good generalization abilities we
applied two common techniques: Normalization and ensemble
building. For normalization we added a small weight decay term
to the loss function that penalizes large weights in the network and
causes the insignificant weights to converge to zero [57].
Ensemble building is a well established method that can
improve model generalization. In general, neural network
ensembles perform better in terms of generalization than single
models would do [58,58,59]. For ensemble building, we followed
a cross-validation strategy: An ensemble of GNNs consists of
several single models that are trained on randomly chosen subsets
of the data with random weight initializations. This ensures the
diversity of the resulting models which is the key issue in ensemble
building. The validation data consists of data points that were hold
out from the training. Only GNN models that perform well on the
validation data are used for the final ensemble. To compute the
ensemble-output for one input sequence, the output variables of all
GNN belonging to the ensemble are averaged. More details of the
GNN training procedure were described in [53].
GNN Models as Fitness Function in a Genetic Algorithm
The main objective in building a GNN model is to recover the
fundamental characteristics of the structure activity relation. The
adapted cells of a fully trained GNN model work as building blocks
of new peptides which are generated by rearranging the order of
the cells and calculating the output of the network. This defines the
fitness function in a genetic algorithm (GA) that is generating new
suggestions for peptide synthesis based on the learned structure
activity relation. The GA performs adaptation by identifying and
recombining schemata, i.e. substrings with above average fitness,
following the building block theory introduced by Holland [60].
We perform mutation and 2-point crossover on the sequence level.
The start population consists of 2000 randomly generated peptide
sequences and evolves over 5000 generations with ‘elitist selection’,
i.e. keeping the best performing individuals of the population
unchanged.
Peptide synthesis and analytics
All peptides were synthesized by peptides&elephants GmbH
(Potsdam, Germany) in 2 mmol scale on a LIPSH 96 peptide
synthesizer. Synthesis was carried out in resin-preloaded MultiPep
96H microtiter plates (peptides&elephants GmbH, Potsdam,
Germany) using Fmoc chemistry on Rink amide AM resin or N-
biotinyl-NFmoc-ethylenediamine-MPB AM resin (Merck Bios-
ciences AG, Darmstadt, Germany). All solvents were of reagent or
HPLC grade and were bought from Carl Roth GmbH (Karlsruhe,
Germany). Temporary Fmoc protection groups were removed by
treatment with 20% piperidine v/v in dimethyl formamide. Amino
acid coupling was done with 4 equiv activated amino acid solution
(0.2 M in N-methyl pyrrolidone). Permanent protection groups
were removed and peptides were released from the resin by
treatment with 90% TFA, 5% triisopropyl silane, 2.5% DTT, and
2.5% HPLC-water v/v. Peptides were lyophilized, redissolved in
TFA, and precipitated by the addition of ice-cold hexane-
diethylether solution (50/50). All peptides were analyzed by MS
(Finnigan Surveyor MSQ Plus, Thermo Finnigan, Bremen,
Germany) to confirm the presence of the correct molecular mass.
For each library synthesized, at least 10 % of the peptides were
analyzed for purity using HPLC. Mean purities of the nonamer
synthesis raw products used in the assays ranged from 78 to 93 %.
Cell Culture and Transfection
HEK293A-cells (Invitrogen) were grown in RPMI 1640
medium buffered with 2.0 g/l NaHCO3 (Biochrom AG) supple-
mented with 10% FCS, 2 mM L-glutamine, penicillin-streptomy-
cin (100 IU/mL; 100 mg/mL) at 37uC in a humidified 5% CO2
incubator. Cells were split into poly-D-lysine coated black-wall 96-
well black well/clear bottom plate (BD Falcon) at a density of
5*10
4 cells/well and cultured for an additional period of 18- to 24-
h. Afterwards, cells stable expressing human Ga15 were transfected
with human CMKLR1 pcDNA3.1 (Missouri S&T cDNA Re-
source Center) construct using the jetPEI (peqlab) transfection
reagent according to the supplier’s protocol. Two days after
transfection, cells were selected in RPMI 1640 medium buffered
with 2.0 g/L NaHCO3 (Biochrom AG), supplemented with 10%
fetal calf serum, 2 mM L-glutamine, penicillin-streptomycin
(100 IU/mL–100 mg/mL), 150 mg/mL zeocin and 300 mg/mL
G418 for a period of 4 weeks (37uC, 5% CO2, 95% relative
humidity). Functional expression of human Ga15 and CMKLR1 in
cells was verified in a CellLux assay recording CMKLR1 / Ga15
mediated intracellular Ca
2+ release upon receptor activation with
chemerin-9, as described below.
Ca
++ Imaging
HEK293A cells (Invitrogen) expressing CMKLR1 and Ga15
were seeded at 5*10
4 cells/well in a poly-D-lysine coated 96-well
black well/clear bottom plate (BD Falcon) and cultured overnight.
From eighteen to twenty-four hours later, cells were loaded with
FLUO4-AM (Invitrogen). Then the cells were washed two times
with C1 solution (130 mM NaCl, 5 mM KCl, 10 mM HEPES pH
7.4, 2 mM CaCl2, and 10 mM Glucose). After the final wash,
a 100 mL of residual volume remained on the cells. Peptides were
dissolved in 10% DMSO to a concentration of 1 mM and were
diluted in C1 solution with 0.1% BSA. They were aliquoted as 2x
solutions in 96-well plates and were simultaneously transferred by
the robotic system within the imager from the ligand plate to the
cell plate. Fluorescence was recorded simultaneously in all wells
using an imaging plate reader CellLux (PerkinElmer) at an
excitation wavelength of 488 nm and emission wavelength of
510 nm at 1.5 s intervals over a period of 4 min. Fluorescence
data was generated in duplicate and experiments were repeated
for at least three times. We tested all compounds at eleven different
concentrations over a range of 5 orders of magnitude. For the
calculation of concentration-response curves, signals of two wells
receiving the same concentration of test substances were averaged
and the fluorescence changes of corresponding buffer C1 wells
were subtracted. Signals were normalized to background fluores-
cence. For the calculation of EC50 values, plots of amplitude versus
concentrations were prepared in SigmaPlot 11. By nonlinear
regression of the plots we were able to calculate the EC50 of
agonist-receptor interaction.
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In vitro peptide stability assays were carried out as previously
described from [61]. Briefly, 500 mL of RPMI supplemented with
25% (v/v) of human serum are allocated into a 1.5 mL Eppendorf
tube and temperature-equilibrated at 3761uC for 15 min before
adding peptide stock solution to make a final peptide concentra-
tion of 50 mg/mL. Dilution of the serum will result in the
proteolytic enzymes being the limiting factor and enable a linear
degradation of the peptides over time. The initial time is recorded,
and at known time intervals 50 mL of the reaction solution is
removed and added to 100 mL of 6% aqueous trichloroacetic acid
(TCA) for precipitation of serum proteins. The cloudy reaction
sample is cooled on ice for 15 min and then spun at 18,000 g
(Eppendorf centrifuge) for 2 min to pellet the precipitated serum
proteins. The reaction supernatant is then analyzed using RP-
HPLC (Agilent 1200 LC System) on a ZORBAX Eclipse XDB-
C18, 4.66150 mm, 5 mm column (Agilent). A linear gradient from
25% to 80% acetonitrile, is used over 15 min with a flow rate of
1 mL/min at 30uC. Absorbance is detected at 214 nm and
280 nm. Fluorescence is detected at an excitation wavelength of
280 nm and emission wavelength of 340 nm. Kinetic analysis was
carried out by least-squares analysis of the logarithm of the
integration peak area versus time.
Sequence analysis
Multiple alignments of peptide sequences and their graphic
representation were generated using the Jalview software package
V2.6.1 [62].
Supporting Information
Table S1 This table provides a complete list of all peptides used
in this study along with their sequence and bioassay data. All
peptides in the start population were amidated variants (indicated
by -NH2 at the end of the sequence). The table also states the
biological activity or potency in the Ca++ mobilizations assay
(EC50), the maximum response in this assay, and the biological half
life in human serum (tK). These data all result from at least three
independent experiments done in duplicate, variation is given as
standard deviation (SD).
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